RXO INC (RXO) Fundamental Analysis & Valuation

NYSE:RXO • US74982T1034

Current stock price

16.24 USD
+0.18 (+1.12%)
At close:
16.3872 USD
+0.15 (+0.91%)
After Hours:

This RXO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. RXO Profitability Analysis

1.1 Basic Checks

  • RXO had negative earnings in the past year.
  • In the past year RXO had a positive cash flow from operations.
  • In multiple years RXO reported negative net income over the last 5 years.
  • Of the past 5 years RXO 4 years had a positive operating cash flow.
RXO Yearly Net Income VS EBIT VS OCF VS FCFRXO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M 300M

1.2 Ratios

  • RXO has a Return On Assets of -3.05%. This is in the lower half of the industry: RXO underperforms 66.67% of its industry peers.
  • Looking at the Return On Equity, with a value of -6.49%, RXO is doing worse than 64.29% of the companies in the same industry.
Industry RankSector Rank
ROA -3.05%
ROE -6.49%
ROIC N/A
ROA(3y)-3.78%
ROA(5y)0.09%
ROE(3y)-7.94%
ROE(5y)1.18%
ROIC(3y)N/A
ROIC(5y)N/A
RXO Yearly ROA, ROE, ROICRXO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 10 -10

1.3 Margins

  • The Gross Margin of RXO (16.39%) is worse than 71.43% of its industry peers.
  • In the last couple of years the Gross Margin of RXO has declined.
  • RXO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 16.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.2%
RXO Yearly Profit, Operating, Gross MarginsRXO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 15

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. RXO Health Analysis

2.1 Basic Checks

  • RXO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • RXO has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, RXO has more shares outstanding
  • Compared to 1 year ago, RXO has a worse debt to assets ratio.
RXO Yearly Shares OutstandingRXO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 50M 100M 150M
RXO Yearly Total Debt VS Total AssetsRXO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • RXO has an Altman-Z score of 2.60. This is not the best score and indicates that RXO is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of RXO (2.60) is comparable to the rest of the industry.
  • RXO has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of RXO (0.25) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z 2.6
ROIC/WACCN/A
WACC10.48%
RXO Yearly LT Debt VS Equity VS FCFRXO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • RXO has a Current Ratio of 1.27. This is a normal value and indicates that RXO is financially healthy and should not expect problems in meeting its short term obligations.
  • RXO has a Current ratio (1.27) which is in line with its industry peers.
  • RXO has a Quick Ratio of 1.27. This is a normal value and indicates that RXO is financially healthy and should not expect problems in meeting its short term obligations.
  • RXO has a Quick ratio (1.27) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.27
RXO Yearly Current Assets VS Current LiabilitesRXO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. RXO Growth Analysis

3.1 Past

  • The earnings per share for RXO have decreased strongly by -145.45% in the last year.
  • RXO shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.20%.
  • RXO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.33% yearly.
EPS 1Y (TTM)-145.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
Revenue 1Y (TTM)26.2%
Revenue growth 3Y6.18%
Revenue growth 5Y11.33%
Sales Q2Q%-11.88%

3.2 Future

  • Based on estimates for the next years, RXO will show a very strong growth in Earnings Per Share. The EPS will grow by 155.84% on average per year.
  • RXO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.55% yearly.
EPS Next Y90.24%
EPS Next 2Y212.21%
EPS Next 3Y155.84%
EPS Next 5YN/A
Revenue Next Year-0.55%
Revenue Next 2Y3%
Revenue Next 3Y4.63%
Revenue Next 5Y9.55%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
RXO Yearly Revenue VS EstimatesRXO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B 8B 10B
RXO Yearly EPS VS EstimatesRXO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 0 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

1

4. RXO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RXO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RXO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXO Price Earnings VS Forward Price EarningsRXO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -1K -2K -3K

4.2 Price Multiples

  • RXO's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. RXO is more expensive than 71.43% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 27.82
RXO Per share dataRXO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • A more expensive valuation may be justified as RXO's earnings are expected to grow with 155.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y212.21%
EPS Next 3Y155.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RXO Dividend Analysis

5.1 Amount

  • No dividends for RXO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RXO Fundamentals: All Metrics, Ratios and Statistics

RXO INC

NYSE:RXO (4/14/2026, 8:04:00 PM)

After market: 16.3872 +0.15 (+0.91%)

16.24

+0.18 (+1.12%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupTransportation
GICS IndustryGround Transportation
Earnings (Last)02-06
Earnings (Next)05-07
Inst Owners108.53%
Inst Owner Change0%
Ins Owners0.84%
Ins Owner Change2.22%
Market Cap2.67B
Revenue(TTM)5.74B
Net Income(TTM)-100.00M
Analysts66.92
Price Target16.4 (0.99%)
Short Float %8.54%
Short Ratio5.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-75.97%
Min EPS beat(2)-79.64%
Max EPS beat(2)-72.3%
EPS beat(4)1
Avg EPS beat(4)-27.69%
Min EPS beat(4)-79.64%
Max EPS beat(4)101.04%
EPS beat(8)5
Avg EPS beat(8)-6.09%
EPS beat(12)8
Avg EPS beat(12)38.1%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2%
Min Revenue beat(2)-2.2%
Max Revenue beat(2)-1.8%
Revenue beat(4)0
Avg Revenue beat(4)-2.86%
Min Revenue beat(4)-5.04%
Max Revenue beat(4)-1.8%
Revenue beat(8)1
Avg Revenue beat(8)-1.36%
Revenue beat(12)2
Avg Revenue beat(12)-2.06%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.61%
EPS NQ rev (1m)-0.84%
EPS NQ rev (3m)-105.48%
EPS NY rev (1m)-136.02%
EPS NY rev (3m)-102.85%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)-5.38%
Revenue NY rev (1m)-0.1%
Revenue NY rev (3m)-3.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.47
P/FCF N/A
P/OCF 52.45
P/B 1.74
P/tB N/A
EV/EBITDA 27.82
EPS(TTM)-0.05
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)0.31
OCFY1.91%
SpS34.86
BVpS9.36
TBVpS-0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -3.05%
ROE -6.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 16.39%
FCFM N/A
ROA(3y)-3.78%
ROA(5y)0.09%
ROE(3y)-7.94%
ROE(5y)1.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.2%
F-Score5
Asset Turnover1.75
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA 3.55
Cap/Depr 50.86%
Cap/Sales 1.03%
Interest Coverage N/A
Cash Conversion 46.79%
Profit Quality N/A
Current Ratio 1.27
Quick Ratio 1.27
Altman-Z 2.6
F-Score5
WACC10.48%
ROIC/WACCN/A
Cap/Depr(3y)66.04%
Cap/Depr(5y)62.51%
Cap/Sales(3y)1.22%
Cap/Sales(5y)1.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-145.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
EPS Next Y90.24%
EPS Next 2Y212.21%
EPS Next 3Y155.84%
EPS Next 5YN/A
Revenue 1Y (TTM)26.2%
Revenue growth 3Y6.18%
Revenue growth 5Y11.33%
Sales Q2Q%-11.88%
Revenue Next Year-0.55%
Revenue Next 2Y3%
Revenue Next 3Y4.63%
Revenue Next 5Y9.55%
EBIT growth 1Y-123.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year133.6%
EBIT Next 3Y84.84%
EBIT Next 5Y60.59%
FCF growth 1Y85.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y525%
OCF growth 3Y-45.21%
OCF growth 5Y15.33%

RXO INC / RXO Fundamental Analysis FAQ

What is the fundamental rating for RXO stock?

ChartMill assigns a fundamental rating of 2 / 10 to RXO.


What is the valuation status for RXO stock?

ChartMill assigns a valuation rating of 1 / 10 to RXO INC (RXO). This can be considered as Overvalued.


How profitable is RXO INC (RXO) stock?

RXO INC (RXO) has a profitability rating of 1 / 10.


Can you provide the financial health for RXO stock?

The financial health rating of RXO INC (RXO) is 3 / 10.